PureTech established the underlying programs and platforms that resulted in 29 therapeutic and therapeutic candidates generated from PureTech's R&D engine, including three taken from inception at PureTech to FDA approval.
Neuropsychiatric conditions
31.2% Equity and 3-5% tiered royalties on Glyph product net sales; modest regulatory and commercial milestone payments
Phase 2
See Our Program
Conditions involving inflammation and fibrosis, including idiopathic pulmonary fibrosis
35.4% Equity
Phase 3
See Our Program
Cobenfy™ (formerly known as KarXT) Now FDA Approved for the Treatment of Schizophrenia in Adults
PureTech retains rights to certain regulatory and commercial milestone payments related to Cobenfy™ in addition to 2% royalties on annual Cobenfy sales above $2B1
FDA Approved
See Our Program
Relapsed/refractory (R/R) high-risk myelodysplastic syndrome (HR-MDS)
100% Equity
Phase 2 Ready
See Our Program

1As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. Additionally, under its license agreement with Karuna/BMS, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals.

Note: Relevant ownership interests in Gallop Oncology as of June 30, 2026; Celea Therapeutics as of July 1, 2026, on a fully diluted basis; and Seaport Therapeutics as of July 27, 2026, based on the common shares outstanding.

PureTech Level Cash, Cash Equivalents

$220.0M
PureTech Level Cash, Cash Equivalents as of June 30, 20261
1 Relevant ownership interests in Gallop Oncology as of June 30, 2026; Celea Therapeutics as of July 1, 2026, on a fully diluted basis; and Seaport Therapeutics as of July 27, 2026, based on the common shares outstanding.

Developing breakthrough medicines at PureTech